XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Item

http://www.wikidata.org/entity/Q37067591

Q37067591

about

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials What do oncologists need to know about biosimilar products?Growth factor use in medication-induced hematologic toxicity.First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Management of neutropenia in cancer patients.Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09 Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation Side effects of cytokines approved for therapy.Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Tbo-Filgrastim: A Review in Neutropenic Conditions.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Onc Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.Follow-on biologics in oncology - the need for global and local regulations.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Biosimilar rhG-CSFs: how similar are they?Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

P2860

Q24198118-27B5B449-CDB2-4C8F-84AF-1969BDA21741 Q27008080-A3C05574-57D2-4321-BD3C-7FD101E0C445 Q28071687-522E00A9-C715-4BCC-9DCC-A1CD938B9C96 Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1A Q33420907-02DF99A8-3589-4E51-A495-97DE7181C9D4 Q33756369-41D5E394-78CA-421A-9FC8-248C9AE823A5 Q33762775-266F6745-4AA1-49AD-B3B4-896D828746B0 Q34029496-D2794113-91E4-4108-8754-2E26AB74E780 Q34333814-C4B32BEA-E8A0-4721-8F1A-4AFFEAB6D811 Q34941030-24ED3534-57AA-4CF3-A82D-D21EF3D67789 Q35633293-8E084CE0-3ABD-4D29-AA55-AAE7B700D4AE Q35835005-9ADA2066-E036-4C7C-BF23-D49C88DEA51B Q36000209-FBBAEB82-68D9-47EE-B378-E4E10D7F3097 Q36452230-6C9DB5D3-5C16-4B8C-9B39-721D41C43CF9 Q36615056-E5697BCF-AAE3-47A5-87DC-3FB18B968BE6 Q36981948-3A8D661D-61B3-4CC1-91CE-D6F2EA900F88 Q37205943-15EB6DB1-26CE-4F47-93FD-DE179330C6D9 Q37616966-152F8781-ACE2-448D-89A7-737282EEB89F Q37675627-3A72488B-7B63-4D3E-824C-8EAB4E81DD1E Q38082542-7FCB92A1-6C9C-4452-A34E-3704D0D87082 Q38125609-D33FC04F-14E2-411F-AF79-6A55314BDE27 Q38186025-BC8DB2E2-1FF0-4A23-BE3D-1F891D1FFEC7 Q38255698-5E424B28-6AA2-48D5-9FDB-164C4A54B803 Q38726241-9F9CA5C2-321B-4133-9727-A7E14B6D35C1 Q38749061-D5E129D6-7BF3-4B39-95CC-EB43CDBB7CD2 Q38792513-88A579FF-2349-44BC-80DE-C112DBEF8E58 Q38969947-0F7FBA17-0846-42EF-8714-A93EA32AA495 Q40094120-D7E79F42-9FD3-47F7-BA68-76FB09C72B64 Q40245653-A4586042-1549-455A-B346-C101E81B3AA6 Q40402240-3B97F0E4-A713-492F-8221-2309D2C37D1F Q42223844-29C838F3-EAB3-4F78-8EB7-3FB0E35C7201 Q42783302-B1BAFA52-287A-43DE-88F1-27C8BFAEA535 Q43121123-9F9EFD89-E6ED-437D-8C69-F8BA754C8A8D Q44894394-6C66C102-95D8-4D65-9AD9-F2AAA9CE7876 Q45788056-C96DB9C7-A05B-4A3A-AB88-6EF713062675 Q47213188-83C4B40A-E323-4F21-B20A-3517206F7C17 Q47938059-ACBA1FE2-E4B3-4B25-9896-1473B9AB23CC Q48273553-BEED1448-D72D-4D1A-959D-E02F046AA008 Q50001689-BB7448D4-684F-40D1-9018-64844C87E828 Q50042993-3C50F0B8-0469-4B09-8341-26FC42748442

P2860

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Item

http://www.wikidata.org/entity/Q37067591

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@en

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@nl

type

Item

label

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@en

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@nl

prefLabel

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@en

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@nl

P1476

XM02 is superior to placebo an ...... axel/doxorubicin chemotherapy.

@en

P2093

A Eniu

http://www.w3.org/2001/XMLSchema#string

A del Giglio

http://www.w3.org/2001/XMLSchema#string

D Ganea-Motan

http://www.w3.org/2001/XMLSchema#string

E Topuzov

http://www.w3.org/2001/XMLSchema#string

H Lubenau

http://www.w3.org/2001/XMLSchema#string

P2860

Granulocyte colony stimulating factors: how different are they? How to make a decision?

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

Colony-stimulating factors for the management of neutropenia in cancer patients.

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.

Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.

P2888

1471-2407-8-332

P304

332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-8-332

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23478750

http://www.w3.org/2001/XMLSchema#string

P6179

1014393182

http://www.w3.org/2001/XMLSchema#string

P698

19014494

http://www.w3.org/2001/XMLSchema#string

P921

patient

placebo

chemotherapy

P932

2628928

http://www.w3.org/2001/XMLSchema#string

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

about

P2860

P2860

XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P478

P577

P5875

P6179

P698

P921

P932